Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
October 24, 2023 07:15 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
October 10, 2023 07:07 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
October 03, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signallingMDNA223...
Medicenna Announces Results of Annual and Special Meeting of Shareholders
September 28, 2023 17:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the...
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
September 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the...
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
August 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment...
Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management
August 14, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent.Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of...
Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
August 09, 2023 07:30 ET
|
Medicenna Therapeutics Corp.
- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete...
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
August 08, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today...